Social media trends are driving people to inject GHK-Cu, a copper peptide, despite a lack of human safety data and concerns over unregulated sourcing.
Key facts
- •GHK-Cu is a naturally occurring molecule that stimulates collagen production and skin remodeling.
- •Topical applications of copper peptides have been studied for decades and are considered safe for skin health.
- •There is no published data from human studies to support the safety or efficacy of injecting GHK-Cu.
- •Medical professionals warn that unregulated online suppliers may provide products with unknown purity or dosage.
- •Reported side effects from self-injection include liver enzyme elevation, infections, and skin irritation.
Copper peptides, specifically GHK-Cu, have gained popularity on social media for claims of anti-aging and skin health benefits. While topical use is well-studied, many individuals are now opting for subcutaneous injections. Experts warn that there is no published human research confirming the safety or efficacy of these injections, and many users are sourcing the substances from unregulated online markets.
Scientific Context and Research
GHK-Cu was first isolated in the early 1970s by chemist Loren Pickart. Research has shown that the peptide stimulates collagen production and has anti-inflammatory effects. While controlled human trials have supported the use of GHK-Cu in creams and serums for skin health, hair growth, and wound healing, these studies are generally small and funded by the cosmetic industry. Pre-clinical research in animals has suggested potential benefits for organ repair and Alzheimer's symptoms, but these findings have not been replicated in human trials.
Risks of Unsupervised Injection
Dermatologists and medical professionals express significant concern regarding the trend of self-injecting GHK-Cu. Potential risks include elevated copper levels, immune reactions, and infections. Because many users obtain these formulations from the grey market, there is no assurance regarding dosage or product purity. Clinicians report seeing patients with complications such as injection site irritation and elevated liver enzymes after self-administering the peptide.
Regulatory Status
GHK-Cu currently exists in a regulatory gray area. Compounding pharmacies in the U.S. are not permitted to offer it for human injection, though a government advisory panel is scheduled to review evidence regarding the peptide in February. Currently, the lack of FDA approval and the difficulty of patenting a naturally occurring molecule mean that large-scale human trials remain unlikely.
Timeline
- Early 1970sChemist Loren Pickart isolated GHK-Cu after observing its effects on liver cells.
- Earlier this summerAn FDA advisory panel recommended reclassifying several peptides.
- FebruaryA government panel will meet to review evidence regarding GHK-Cu as an injectable.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by NPR Health.
